Your browser does not support JavaScript or it may be disabled!
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
Get Realtime News
on your webpage

About 476 results for "sun pharma advanced research"

Pharmalot, Pharmalittle: The debate over data sharing heats up again

Sun Pharma arm stops research on cancer drug and other top pha...

Teva Pharmaceutical Industries will focus on the integration of Allergan's generics business into its operations, it said on Thursday, after completing the $40.5 billion deal this week. Sun Pharma Advanced Research Company, or SPARC, has ... India Infoline, 3 weeks ago
Buy SPARC, says Mitesh Thacker Money Control, 3 weeks ago

48 images for sun pharma advanced research

India Infoline, 3 months ago
Business Standard India, 1 month ago
Business Standard India, 1 month ago
Financial Express, 1 month ago
The Freepress Journal, 1 month ago
India Infoline, 1 month ago
India Infoline, 1 month ago
India Infoline, 5 months ago, 1 day ago
Sify, 2 weeks ago
Financial Express

SPARC gains over 7 per cent intraday on licence pact

MUMBAI: Shares of Dilip Shanghvi-promoted Sun Pharma Advance Research Company (SPARC) jumped more than 7 per cent in Monday's trading, after the company announced that it will out-license its anti-epileptic drug ELEPSIA to Sun Pharmaceutical ...
 Economic Times1 month ago SPARC shares surge over 7% intraday on inking licensing pact with Sun Pharma  Financial Express1 month ago SPARC shares surge over 7% on inking licensing pact with Sun Pharma  NewsFlow241 month ago

SPARC Licenses Epilepsy Drug to Sun Pharma

Sun Pharma Advanced Research Company and Sun Pharma announced a licensing arrangement for SPARC's ELEPSIA XRTM (Levetiracetam Extended Release tablets). As per the agreement, SPARC will license ELEPSIA XRTM (Levetiracetam Extended Release ...
 PharmaAsia1 month ago SPARC jumps after entering into licensing arrangement with Sun Pharma  Business Standard1 month ago Sun Pharma partners SPARC to market epilepsy drug in US  Livemint.com1 month ago

Pick ICICI Bank, SPARC, GIC Housing: Vijay Chopra

Vijay Chopra of is of the view that one may pick ICICI Bank and Sun Pharma Advanced Research Company.
 Money Control1 month ago Here's why Canara Bank, pharma cos, Texmaco Rail are in news  Money Control1 month ago Sensex, Nifty50 start on a cautious note; Eicher Motors up 6%  Economic Times4 weeks ago Sensex, Nifty50 flat; JP Associates surges 6%, Infosys slips 1%  Economic Times1 month ago

Buy SPARC, Magma Fincorp, Balrampur Chini, JK Lakshmi: Gujral

Ashwani Gujral of recommends buying Sun Pharma Advance Research Company, Magma Fincorp, Balrampur Chini and JK Lakshmi Cement.
 Money Control1 month ago Buy Sun Pharma Advanced, Mercator, MM Financial: Ashwani Gujral  Money Control1 month ago Buy Dena Bank, SREI Infra, Biocon, Sun Pharma Adv: Gujral  Money Control2 months ago
IndUS Business Journal

Sun Pharma gets epilepsy drug licence for US market

Chennai, July 18 (IANS): Sun Pharmaceutical group on Monday announced the licensing of ELEPSIA XR drug by Sun Pharma Advanced Research Company Ltd (SPARC) to a subsidiary of Sun Pharmaceutical Industries Ltd for the US market. In a statement, Sun ...
 Daijiworldcom1 month ago

Sensex advances 128 points on pharma booster dose

Markets advanced for a second day as the BSE Sensex gained 128 points to 27,915, mainly led by pharmaceutical stocks after three Indian firms received nod to sell their generic versions of blockbuster Crestor drug in the American market. Sentiment also remained buoyant as a good monsoon season so far lifted hopes of a revival in farm output as well as income and on optimism over the Goods and Services Tax bill's passage. Shares of Sun Pharma, Glenmark and Aurobindo were the star performers, ...
 Rediff.com1 month ago Sensex advances 128 pts on pharma booster dose  Press Trust of India1 month ago Stock markets advance on pharma dose  The Freepress Journal1 month ago Sensex advances 128 pts on ph...  The Echo Of India1 month ago
IOL Business Report

Big Pharma drawn back to antibiotics

File picture. Credit: SXC.HU With the planet on the brink of losing its miracle cures for bacterial diseases, research incentives from governments are spurring drugmakers to renew efforts to fight antimicrobial resistance and replenish the ...
 IOL Business Report1 month ago There's Big Money Again in Saving Humanity With Antibiotics  PharmaVOICE1 month ago Superbugs and Subsidies Draw Big Pharma Back to Antibiotics  Bloomberg1 month ago Superbugs, subsidies draw big pharma back to antibiotics  Business Mirror1 month ago

Sensex advances on pharma booster dose

Sensex opened slightly lower at 27,775.70 and moved between 27,935.18 and 27,759.71, before ending at 27,915.89, showing a rise of 128.27 points. Market advanced for a second day as the BSE Sensex gained 128.27 points to 27,915.89, mainly led by ...
 The Hindu1 month ago

Key Pharma News Issue - Rising Trial Risk Will Promote Novel Methods Of Drug Development - Research and Markets

Research and Markets has announced the addition of the "Key Pharma News Issue 51" report to their offering. CNS disorders will retain huge commercial opportunities and see continued investment despite the high cost of development and risk of trial ...
 4 Traders2 months ago Analyzing the Biotechnology Industry in India 2016 - Research and Markets  Financial Buzz1 month ago Global Retinitis Pigmentosa Pipeline Report 2016 - Research and Markets  4 Traders1 month ago World Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) Pipeline Report 2016 - Research and Markets  4 Traders2 months ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts


Realtime News

on your Webpage

Add Widget >Get your members hooked!
Related Queries - sun pharma advanced research
Get updated on latest news & your favorite topics right in your inbox!
More     Less